Beamtree Holdings Ltd · ASX:BMT
Beamtree — IPO Roadshow (June 2019)
40 slides from Beamtree's IPO roadshow presentation, Jun 14, 2019
Slide 1: PKS Holdings IPO Presentation
PKS Holdings IPO Presentation April 2019
Slide 2: Important notices
Important notices The information contained in this presentation or subsequently provided to any recipient of this presentation whether orally or in writing by or on behalf of Qpro Holdings Limited to be renamed PKS Holdings Limited (PKS) or its respective employees, agents or consultants (Informati
Slide 3: Agenda
Agenda 1. Introduction and Investment Highlights 2. Business Overview 3. Growth Strategy 4. Financial Overview 5. Senior Management Team and Board 6. Indicative Capital Structure and Timetable 7. Selected Key Risks PKS Holdings – March 2019 Page 3
Slide 4: Introduction and Investment Highlights
Introduction and Investment Highlights PKS Holdings – March 2019
Slide 5: Introduction to PKS
Introduction to PKS Overview ▪ PKS Holdings Ltd (PKS) is a healthcare technology company which provides a proprietary subscription based Clinical Decision Support (CDS) system called “RippleDown” that automates the human decision-making process in health care organisations ▪ RippleDown has two compo
Slide 6: Key Investment Highlights
Key Investment Highlights PKS represents an opportunity to participate in the large and fast growing global Healthcare IT solutions market ▪ Clinical Decision Support (CDS) software ▪ Demonstrated cost savings for institutions 1 World-class proprietary health technology ▪ Originated in the UNSW Scho
Slide 7: Business Overview
Business Overview PKS Holdings – March 2019
Slide 8: Pressures on Healthcare Organisations
Pressures on Healthcare Organisations RippleDown addresses the following major issues within healthcare organisations ▪ Public and private health systems have been facing revenue pressures and declining margins Financial Pressures ▪ Healthcare budgets are under pressure, labour costs are rising and
Slide 9: PKS provides the RippleDown Software solution
PKS provides the RippleDown Software solution RippleDown has two components that address the pressures faced by healthcare organisations: Auditor and Expert ▪ RippleDown Auditor is a knowledge based system that allows multiple departments (including data entry, billing and specimen reception) to aud
Slide 10: RippleDown Auditor – How it works
RippleDown Auditor – How it works RippleDown Auditor verifies information in real time Stage 1 – Implementation to maturity Stage 2 – After maturity Patient A Physician X Patient B Physician Y Patient A is treated Patient B is treated 1 1 by Physician X by Physician Y Patient A data (eg name, DOB, M
Slide 11: RippleDown Auditor – How it works
RippleDown Auditor – How it works RippleDown Auditor flags potential errors and allows errors to be corrected before they cost the organisation money Example of RippleDown Auditor Incorrect Medicare number – Medicare would not pay Incorrect test ordered – Vitamin D test not required again Auditor en
Slide 12: RippleDown Auditor – How it works
RippleDown Auditor – How it works RippleDown Auditor enables errors to be corrected in real time Example of RippleDown Auditor dashboard Impact of RippleDown ▪ Nearly 1.5m episodes processed by this organisation in the last 12 months ▪ ~400k were flagged for review (eg change in patient address, inc
Slide 13: RippleDown Expert – How it works
RippleDown Expert – How it works The RippleDown product evolves over time as rules are incorporated Stage 1 – Implementation to maturity Stage 2 – After maturity Patient A Physician X Patient B Physician Y Patient A is treated Patient B presents with 1 1 by Physician X same symptoms as Patient A 2 P
Slide 14: RippleDown Expert – How it works
RippleDown Expert – How it works The provision of interpretations based on a rich history of patient cases is the key differentiator that makes RippleDown different from other CDS Example of RippleDown Expert Significant value-add LDL = 5.8mmol/L Typical or Examines patient report history LDL is abo
Slide 15: RippleDown Expert – How it works
RippleDown Expert – How it works RippleDown improves the clinical experience through auto validation, use of multiple patient data sources and the capture of a rich history of cases Example of a RippleDown Expert dashboard Impact of RippleDown ▪ Over 10.6 million interpretations processed by this or
Slide 16: RippleDown – Competitive Position
RippleDown – Competitive Position RippleDown has a number of key advantages against competitors that enables it to continue to win new business RippleDown Typical Competitors The client’s experts (e.g. Pathologists, Who builds the rules? A team of IT professionals Cardiologist) without any IT involv
Slide 17: RippleDown – Customer Case Studies
RippleDown – Customer Case Studies RippleDown provides significant benefits for healthcare organisations Australian Public Health Organisation African Laboratory Business US Hospital This pathology organisation, delivers laboratory This business is one of the leading pathology This hospital is an ac
Slide 18: Customers: Global Business
Customers: Global Business PKS has already gained a global footprint with significant opportunity to grow through partnerships and direct sales in target geographies FY181 Customer Revenue, by Region Partner A Europe USA 13% 20% Gribbles Pathology Malaysia Asia2 South Africa Australia 23% 38% NZ 6%
Slide 19: Growth Strategy
Growth Strategy PKS Holdings – March 2019
Slide 20: Key Growth Strategies
Key Growth Strategies PKS has a range of growth strategies Selective acquisitions ▪ Selective Price increases acquisitions to add technology and / or Product ▪ Opportunity to customers roadmap increase pricing for new contracts Direct sales ▪ Cloud strategy ▪ Complement model existing rules New chan
Slide 21: Growth through channel partners
Growth through channel partners Channel partners are an important route to market, providing a range of advantages Channel partner summary Strong pipeline of projects ▪ PKS has 3 channel partners ‒ Abbott Laboratories ‒ Philips ‒ Thermo Fisher 250 26 Strong growth trajectory 21 200 18 16 150 108 11
Slide 22: Growth through direct sales
Growth through direct sales Direct sales will be an increasing focus going forward Direct Sales – Summary Direct Sales – Existing customers ▪ PKS has had limited direct sales in last two years while an exclusivity arrangement with a partner was in effect ▪ Direct sales opportunity to further enhance
Slide 23: Growth Opportunities
Growth Opportunities PKS has a clear growth path, with plans to grow through existing partners, new partners and direct sales Existing Partners New Partners Direct Sales Example: ~A$22,000 in first year, approximately one third being an up- Average ~A$160,000 revenue per Revenue model Pricing to be
Slide 24: PKS has historically not invested for growth
PKS has historically not invested for growth Since 2016, PKS has focused on regulatory approvals and a single channel partner 2015 2016 2017 2018 IPO 2019 Invest in Technology Invest in Partnership & Regulatory Invest for Global Growth ▪ Michael Reakes joins the ▪ Licence agreement ▪ Meet external a
Slide 25: Financial Overview
Financial Overview PKS Holdings – March 2019
Slide 26: PKS is a high margin business with a high % of recurring revenues
PKS is a high margin business with a high % of recurring revenues Revenues and EBITDA margin has grown over the last three years High margin business 80% of revenue from recurring license fees (1) 6.0 54% 60.0% 38% 5.0 40.0% 3.9 A$m June Y/E 17% 3.9 4.0 20.0% 3.5 3.5 Government grants 0.8 3.0 3.0 0.
Slide 27: Financial performance
Financial performance Recurring revenue growth is inherent in business model as customer knowledge bases increase in size and usage increases naturally. As sales resources are added and the customer base increases, this naturally occurring growth is expected to accelerate. Summarised Financial Perfo
Slide 28: Financial position
Financial position PKS will be debt free post IPO Pro Forma Consolidated Statement of Financial Position Commentary A$000 31-Dec-18 ▪ The table at left presents the Pro Forma Statement of Financial Position of PKS as at Current Assets 31 December 2018 allowing for adjustments occurring prior to the
Slide 29: Cash flow
Cash flow Cash conversion is strong Cash flow statement Commentary A$000 FY2017 FY2018 HY2018 HY2019 Cash flows EBITDA 1,315 2,105 1,101 1,159 Management fees (2,000) ▪ PKS’s statutory cashflow statement is shown in the table on the left. Non-cash items in EBITDA (15) - - - Changes in working capita
Slide 30: Senior Management Team and Board
Senior Management Team and Board PKS Holdings – March 2019
Slide 31: Senior Management Team
Senior Management Team PKS is led by a highly experienced management team RonChris Smith van der Pluijm Michael Reakes Lindsay Peters Andrew Bursill Evan Simmons MDDirector CEO and CEO General Manager CTO CFO and Company Product Manager Secretary ▪ Ron van der Pluijm has been ▪ Michael Reakes has be
Slide 32: Proposed Board
Proposed Board Subject to a successful capital raising, the Board will consist of… Chris Ron Chrisvan der Andrew Gray MikeSmith Hill Smith Paul Williams Neil Broekhuizen Chris Smith Pluijm Non-Executive Director Director CEO Non-Executive Director CEO Non-Executive Director Non-Executive Director Ad
Slide 33: Indicative Capital Structure and Timetable
Indicative Capital Structure and Timetable PKS Holdings – March 2019
Slide 34: Capital Structure and Sources and Uses of Funds
Capital Structure and Sources and Uses of Funds Funds being raised to acquire the PKS business, provide working capital for growth and pay costs of the Offer ▪ The acquisition vehicle currently has approximately 70 shareholders with approximately $0.75 million raised to fund acquisition due diligenc
Slide 35: Timetable
Timetable PKS is planning to list on the ASX in May 2019 Key Events and Indicative Timetable Event Date Management Roadshow 8-12 April 2019 Bookbuild 15 April 2019 Allocations advised 15 April 2019 Prospectus lodged with ASIC 16 April 2019 Opening Date of the Offer 3 May 2019 Closing Date of the Off
Slide 36: Selected Key Risks
Selected Key Risks PKS Holdings – March 2019
Slide 37: Selected Key Risks
Selected Key Risks Channel Partner Risk ▪ PKS distributes its products via two key channels, being direct sales using its own sales resources and through three global channel partners. Given the significant portion the channel partner sales represents, if channel partners failed to deliver in the fu
Slide 38: Selected Key Risks
Selected Key Risks Intellectual Property ▪ There is a risk that the Company may be unable to detect the unauthorised use of its intellectual property rights in all instances. Customer Service ▪ The Company’s business model is based on recurring revenue arising from the provision of software. Whilst
Slide 39: Foreign jurisdiction disclaimers
Foreign jurisdiction disclaimers This document does not constitute an offer of Shares in any Hong Kong United States jurisdiction in which it would be unlawful. In particular, this WARNING: This document has not been, and will not be, This presentation may not be released or distributed in the docum
Slide 40: Pacific Knowledge Systems
Pacific Knowledge Systems